About 100 Mg - Vial Azacitidine Injection
Take advantage of this Last Chance to secure the exclusive 100 Mg - Vial Azacitidine Injection at a reduced price! This exceptional lyophilized powder is best suited for the treatment of Myelodysplastic Syndromes (MDS), refractory anemia, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML). Each vial contains gorgeous, hospital-grade Azacitidine-ready for reconstitution for subcutaneous or intravenous injection. Strictly prescription-only, this premium product offers safe, sterile, and pyrogen-free quality, exported internationally and supplied domestically. Limited stock-order today for uncompromised patient care.
Key Features: Application, Material, and Distinct Benefits
Used extensively in oncology, hospitals, and clinical settings, the 100 Mg - Vial Azacitidine Injection provides robust treatment for MDS and related hematological conditions. The formulation features pure Azacitidine with excipients, delivered as a sterile, pyrogen-free, lyophilized powder that is easily reconstituted. With a stable neutral pH (6.5-7.5) once reconstituted, this product is both odorless and simple to store, offering a shelf life of 24 months and outstanding clinical reliability.
Sample Policy, Certification, and Logistics Details
Samples of the 100 Mg - Vial Azacitidine Injection are available, enabling evaluation before any bulk purchase. Our competitive rate structure ensures value-for-money outlay on all goods provided. Certified and quality assured, each batch conforms to international standards. All goods are efficiently transported to ensure freshness upon delivery, backed by comprehensive export documentation. For further details on sample requests or certifications, please connect with our trusted distributor or supplier networks.
FAQ's of 100 Mg - Vial Azacitidine Injection:
Q: How is the 100 Mg - Vial Azacitidine Injection administered?
A: The injection is administered either subcutaneously or intravenously after thorough reconstitution with sterile water for injection by a qualified healthcare professional.
Q: What are the main indications for prescribing Azacitidine Injection?
A: This injection is primarily indicated for treating Myelodysplastic Syndromes (MDS), refractory anemia, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML).
Q: When should the reconstituted solution be used?
A: Once reconstituted, the solution remains stable for up to 22 hours when stored at 2-8C and should be used within this period for maximum efficacy and safety.
Q: Where can this product be supplied or exported?
A: The 100 Mg - Vial Azacitidine Injection is available for both international export and domestic supply, with distribution coverage across multiple regions.
Q: What are the primary usage benefits of this injection?
A: Azacitidine offers targeted cytotoxic effects against cancer cells in hematological malignancies, providing an effective therapeutic option for eligible patients.
Q: What should be checked before administering this product?
A: Ensure the patient is not hypersensitive to Azacitidine or any of the formulation's components, and confirm prescription status prior to administration.